CHICAGO--(BUSINESS WIRE)--Kicking off the new year with an eye toward improving accuracy and efficiency in Pap testing for the deadly Human Papillomavirus (HPV), CytoCore, Inc. (OTCBB:CYCR) today announced a fast-tracked marketing trial to demonstrate their e2 Collector’s™ superior, more thorough cell sampling technology.
